| First Author | Kircher DA | Year | 2019 |
| Journal | Mol Cancer Res | Volume | 17 |
| Issue | 9 | Pages | 1787-1800 |
| PubMed ID | 31138602 | Mgi Jnum | J:279045 |
| Mgi Id | MGI:6360388 | Doi | 10.1158/1541-7786.MCR-18-1372 |
| Citation | Kircher DA, et al. (2019) AKT1(E17K) Activates Focal Adhesion Kinase and Promotes Melanoma Brain Metastasis. Mol Cancer Res 17(9):1787-1800 |
| abstractText | Alterations in the PI3K/AKT pathway occur in up to 70% of melanomas and are associated with disease progression. The three AKT paralogs are highly conserved but data suggest they have distinct functions. Activating mutations of AKT1 and AKT3 occur in human melanoma but their role in melanoma formation and metastasis remains unclear. Using an established melanoma mouse model, we evaluated E17K, E40K, and Q79K mutations in AKT1, AKT2, and AKT3 and show that mice harboring tumors expressing AKT1(E17K) had the highest incidence of brain metastasis and lowest mean survival. Tumors expressing AKT1(E17K) displayed elevated levels of focal adhesion factors and enhanced phosphorylation of focal adhesion kinase (FAK). AKT1(E17K) expression in melanoma cells increased invasion and this was reduced by pharmacologic inhibition of either AKT or FAK. These data suggest that the different AKT paralogs have distinct roles in melanoma brain metastasis and that AKT and FAK may be promising therapeutic targets. IMPLICATIONS: This study suggests that AKT1(E17K) promotes melanoma brain metastasis through activation of FAK and provides a rationale for the therapeutic targeting of AKT and/or FAK to reduce melanoma metastasis. |
